Q1 2025 Pulse Biosciences Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: $16.85 (+0.96%)

Transcript 10-Q8-K

Key Points

Positve

Pulse Biosciences Inc (PLSE) has received 7 FDA clearances and a breakthrough device designation for its cardiac surgical clamp, validating its technology.
The company has treated over 6,000 patients, demonstrating the practical application and acceptance of its technology.
Clinical data presented at major medical conferences show promising results for the company's NSPFA technology in treating atrial fibrillation and thyroid nodules.
Pulse Biosciences Inc (PLSE) raised $14 million through the exercise of warrants, maintaining its cash position at 2024 year-end levels.
The company is expanding its commercial infrastructure and has identified multiple sites for its next study, indicating strong future growth potential.

Negative

Total GAAP costs and expenses increased significantly by $7.4 million to $18 million compared to the prior year period.
The company reported a GAAP net loss of $16.8 million in the first quarter of 2025, up from $10.1 million in the prior year period.
Non-GAAP net loss also increased to $11.4 million from $8.1 million in the prior year period.
Cash use in operating activities increased to $13.5 million compared to $9.8 million in the previous year.
The company is still in the early stages of commercialization, with revenue generation expected only in the second half of 2025.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PLSE.OQ - Pulse Biosciences Inc
Q1 2025 Pulse Biosciences Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, ladies and gentlemen, and welcome to the Pulse Biosciences first quarter 2025 financial results conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press 0 for the operator.

This call is being recorded on Thursday, May 8, 2025.

I would like to hand over the conference to the first speaker today, Trip Taylor, Investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.